(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/109501 A2

(51) International Patent Classification:
C12N 5/0783 (2010.01) *A61P 35/00* (2006.01)
A61K 35/17 (2015.01)

(21) International Application Number:
PCT/US2021/060667

(22) International Filing Date:
23 November 2021 (23.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/198,933	23 November 2020 (23.11.2020)	US
63/146,477	05 February 2021 (05.02.2021)	US
63/153,922	25 February 2021 (25.02.2021)	US
63/165,023	23 March 2021 (23.03.2021)	US
63/167,592	29 March 2021 (29.03.2021)	US
63/181,218	28 April 2021 (28.04.2021)	US
63/273,138	28 October 2021 (28.10.2021)	US

(71) Applicant: **LYELL IMMUNOPHARMA, INC.** [US/US]; 201 Haskins Way, South San Francisco, California 94080 (US).

(72) Inventors: **VODNALA, Suman Kumar**; 201 Haskins Way, South San Francisco, California 94080 (US). **PATEL, Yogin**; 201 Haskins Way, South San Francisco, California 94080 (US). **RESTIFO, Nicholas P.**; 201 Haskins Way, South San Francisco, California 94080 (US).

(74) Agent: **KIM, Ji Eun** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: METHODS FOR CULTURING IMMUNE CELLS

(57) Abstract: The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of $CD8^+$ TILs, relative to $CD4^+$ TILs. In some aspects, the methods further increase the number of less-differentiated cells, *e.g.*, less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumorreactive, *e.g.*, tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells, *e.g.*, the TILs, are administered to a subject in need thereof.

WO 2022/109501 A2